Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/181737
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chaparro, María | - |
dc.contributor.author | Garre, Ana | - |
dc.contributor.author | Iborra, Marisa | - |
dc.contributor.author | Sierra Ausín, Mónica | - |
dc.contributor.author | Barreiro de Acosta, Manuel | - |
dc.contributor.author | Fernández Clotet, Agnès | - |
dc.contributor.author | Castro, Luisa de | - |
dc.contributor.author | Boscá Watts, Maia | - |
dc.contributor.author | Casanova, María José | - |
dc.contributor.author | López García, Alicia | - |
dc.contributor.author | Lorente, Rufo | - |
dc.contributor.author | Rodríguez, Cristina | - |
dc.contributor.author | Carbajo, Ana Y. | - |
dc.contributor.author | Arroyo, María Teresa | - |
dc.contributor.author | Gutiérrez, Ana | - |
dc.contributor.author | Hinojosa, Joaquín | - |
dc.contributor.author | Martínez Pérez, Teresa | - |
dc.contributor.author | Villoria, Albert | - |
dc.contributor.author | Bermejo, Fernando | - |
dc.contributor.author | Busquets, David | - |
dc.contributor.author | Camps, Blau | - |
dc.contributor.author | Cañete, Fiorella | - |
dc.contributor.author | Manceñido, Noemí | - |
dc.contributor.author | Monfort, David | - |
dc.contributor.author | Navarro Llavat, Mercè | - |
dc.contributor.author | Pérez Calle, José Lázaro | - |
dc.contributor.author | Ramos, Laura | - |
dc.contributor.author | Rivero, Montserrat | - |
dc.contributor.author | Angueira, Teresa | - |
dc.contributor.author | Camo Monterde, Patricia | - |
dc.contributor.author | Carpio, Daniel | - |
dc.contributor.author | García de la Filia, Irene | - |
dc.contributor.author | González Muñoza, Carlos | - |
dc.contributor.author | Hernández, Luís | - |
dc.contributor.author | Huguet, José M. | - |
dc.contributor.author | Morales, Víctor J. | - |
dc.contributor.author | Sicilia, Beatriz | - |
dc.contributor.author | Vega, Pablo | - |
dc.contributor.author | Vera, Isabel | - |
dc.contributor.author | Zabana, Yamile | - |
dc.date.accessioned | 2021-12-09T16:03:20Z | - |
dc.date.available | 2022-04-01T05:10:24Z | - |
dc.date.issued | 2021-04-01 | - |
dc.identifier.issn | 1873-9946 | - |
dc.identifier.uri | http://hdl.handle.net/2445/181737 | - |
dc.description.abstract | Abstract Background: The development program (UNIFI) has shown promising results of ustekinumab in ulcerative colitis (UC) treatment that should be confirmed in clinical practice. Aims: To evaluate the durability, effectiveness and safety of ustekinumab in UC in real-life. Methods: Patients included in the prospectively maintained ENEIDA registry who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score (PMS) >2] were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at week 16. Results: A total of 95 patients were included. At week 16, 53% of patients had response (including 35% of patients in remission). In the multivariate analysis, elevated serum C-reactive protein was the only variable significantly associated with lower likelihood of achieving remission. Remission was achieved in 39% and 33% of patients at weeks 24 and 52, respectively. Thirty-six percent of patients discontinued the treatment with ustekinumab during a median follow-up of 31 weeks. The probability of maintaining ustekinumab treatment was 87% at week 16, 63% at week 56, and 59% at week 72; primary failure was the main reason for ustekinumab discontinuation. No variable was associated with risk of discontinuation. Three patients reported adverse events; one of them had a fatal severe SARS-CoV-2 infection. Conclusions: Ustekinumab is effective both in the short and the long-term in real-life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1093/ecco-jcc/jjab070 | - |
dc.relation.ispartof | Journal of Crohn's and Colitis, 2021, vol. 15, num. 11, p. 1846-1851 | - |
dc.relation.uri | https://doi.org/10.1093/ecco-jcc/jjab070 | - |
dc.rights | cc-by-nc-nd (c) European Crohn's and Colitis Organisation (ECCO), 2021 | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Colitis ulcerosa | - |
dc.subject.classification | Anticossos monoclonals | - |
dc.subject.other | Ulcerative colitis | - |
dc.subject.other | Monoclonal antibodies | - |
dc.title | Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 711871 | - |
dc.date.updated | 2021-12-09T16:03:20Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
711871.pdf | 501.43 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License